Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Voyager Therapeutics Earnings Highlights: Advancing CNS Gene Therapy Pipeline and Tau-Targeting Programs

by Team Lumida
August 7, 2024
in Equities
Reading Time: 8 mins read
A A
0
Voyager Therapeutics Earnings Highlights: Advancing CNS Gene Therapy Pipeline and Tau-Targeting Programs
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Voyager Therapeutics demonstrates progress in its CNS gene therapy pipeline and tau-targeting programs for Alzheimer’s disease, positioning the company for potential value creation in the coming years.

Top Takeaways

  1. Voyager’s anti-tau antibody VY-7523 has entered Phase 1a trials, with topline data expected in H1 2025.
  2. Three gene therapy programs are on track for IND filings in 2025, including the wholly-owned SOD1 ALS program.
  3. The company’s TRACER platform continues to yield promising capsids for CNS gene therapy delivery.
  4. Strong cash position of $371 million provides runway through multiple clinical data readouts into 2027.
  5. Partnerships with Neurocrine, Novartis, and Alexion could generate up to $8.2 billion in long-term milestone payments.

Summary

Voyager Therapeutics reported significant progress in Q2 2024, advancing its pipeline of CNS gene therapy and antibody programs. The company dosed the first healthy volunteers in the Phase 1a trial of VY-7523, its anti-tau antibody for Alzheimer’s disease. Additionally, Voyager completed a pre-IND meeting with the FDA and initiated GLP toxicology studies for VY-9323, its SOD1 silencing gene therapy program for ALS.

“At Voyager, we are leveraging the power of human genetics to discover and develop transformative medicines that address the root cause of neurological diseases. We have made tremendous progress toward this goal in 2024, including the achievement of several important milestones in the Q2.” – Dr. Al Sandrock, CEO

Main Themes

  • Guidance: Cash runway extended into 2027, supporting multiple clinical data readouts
  • New Product Announcements: Development candidate selected for GBA1 gene therapy program partnered with Neurocrine
  • AI references: None mentioned
  • Market-moving information: Three gene therapy programs tracking to INDs in 2025
  • Economic outlook: Not discussed

Insights

Voyager’s TRACER platform continues to demonstrate robust transduction of key CNS cell types and significant liver detargeting following a single IV dose. This technology has enabled the selection of multiple development candidates in both wholly-owned and partnered gene therapy programs, potentially addressing a critical challenge in CNS drug delivery.

Market Opportunity

Voyager is targeting high unmet needs in neurological diseases, particularly Alzheimer’s disease and genetic forms of ALS. The company’s dual approach to targeting tau in Alzheimer’s disease, through both an antibody and gene therapy, could potentially address a significant market opportunity given the limitations of current treatments.

Market Commentary

The CNS gene therapy space is evolving rapidly, with multiple companies pursuing novel capsid designs for improved delivery across the blood-brain barrier. Voyager’s TRACER platform positions the company competitively in this field, with the potential to yield capsids tailored to specific diseases and cell types.

Regulatory Policy

Voyager completed a pre-IND meeting with the FDA for its SOD1 ALS program, indicating progress towards clinical development. The company is also leveraging regulatory pathways established by other approved therapies, such as in Friedreich’s ataxia, to guide its development strategies.

Industry Insights

The progress of Voyager’s programs could have implications for other players in the CNS gene therapy and Alzheimer’s disease treatment spaces. The company’s success in developing novel capsids and targeting tau could validate these approaches for the broader industry.

Key Metrics

Financial Metrics

  • Cash position: $371 million as of Q2 2024
  • Runway: Into 2027

KPIs

  • VY-7523 (anti-tau antibody): Phase 1a trial initiated
  • Gene therapy programs: 3 INDs expected in 2025
  • Partnered programs: Up to $8.2 billion in potential milestone payments

“We ended the 2nd quarter with a strong cash position of approximately $371,000,000 which based on our current operating plans, we expect to provide runway through multiple clinical data readouts into 2027.” – Dr. Al Sandrock, CEO

Competitive Differentiators

  1. TRACER platform for novel AAV capsid discovery
  2. Dual approach to targeting tau in Alzheimer’s disease
  3. Strong partnerships with Neurocrine, Novartis, and Alexion
  4. Focus on genetically validated targets
  5. Potential for rapid proof of biology in clinical programs

Key Risks

  1. Clinical trial risks, particularly for novel gene therapies
  2. Competitive landscape in Alzheimer’s disease and CNS gene therapy
  3. Regulatory hurdles for advanced therapies
  4. Dependence on partnerships for some programs
  5. Long-term safety concerns for gene therapies and tau-targeting approaches

Analyst Q&A Focus Areas

  • Cadence of gene therapy program IND filings
  • Competitive positioning of anti-tau therapies
  • Potential for multi-organ specificity of TRACER-derived capsids
  • Mechanism of liver detargeting in novel capsids
  • Pros and cons of targeting extracellular vs. intracellular tau

Voyager Therapeutics Summary:

Voyager Therapeutics is making significant strides in advancing its CNS gene therapy pipeline and tau-targeting programs for Alzheimer’s disease. With multiple clinical milestones expected in the next 12-24 months, a strong cash position, and valuable partnerships, the company is well-positioned to potentially create significant value in the near and long term. Investors should watch for upcoming clinical data readouts, particularly from the VY-7523 Phase 1a trial and the progression of gene therapy programs towards IND filings in 2025.

Tags: EARNINGSVoyager
Previous Post

Uber Q2 2024 Earnings Highlights: Strong Growth With Record Profitability

Next Post

Progyny Q2 2024 Earnings Highlights: Challenges in Utilization Patterns Impact Outlook

Recommended For You

Worthington Steel Q1: Sales Up, Profit Rises on Direct Volumes

by Team Lumida
2 weeks ago
person grinding pipe steel wool photography

Key Takeaways Powered by lumidawealth.com Revenue rose 5% year‑over‑year to $872.9M and first‑quarter net income increased to $36.8M ($0.72/share); adjusted EPS was $0.77. Direct tons sold climbed ~6% (Sitem...

Read more

JD Sports Reports Revenue Rise, Profit Dip

by Team Lumida
2 weeks ago
JD Sports Reports Revenue Rise, Profit Dip

Key Takeaways Powered by lumidawealth.com Revenue rose 20% year‑over‑year at constant currency to £5.94 billion for the period ended Aug. 2. Adjusted pretax profit fell to £351 million from...

Read more

Cracker Barrel Shares Tumble After First Earnings Report Since Failed

by Team Lumida
3 weeks ago
Cracker Barrel Shares Tumble After First Earnings Report Since Failed

Key Takeaways Powered by lumidawealth.com Cracker Barrel shares fell 9% to $45.10 after projecting 4-7% guest traffic decline and revenue of $3.35-3.45 billion for fiscal year The company expects...

Read more

TSMC’s August Sales Climb 34% in Latest Sign of Solid AI Demand

by Team Lumida
4 weeks ago
Taiwan Exports Surge 23.5% in June: AI Demand Fuels Massive Growth

Key Takeaways Powered by lumidawealth.com Taiwan Semiconductor Manufacturing Co. (TSMC) reported a 34% increase in August revenue, reaching NT$335.8 billion ($11.1 billion). The strong sales reflect sustained global demand...

Read more

GameStop Sales, Profit Rise on Collectibles and Hardware Growth

by Team Lumida
4 weeks ago
black android smartphone on black textile

Key Takeaways Powered by lumidawealth.com GameStop’s Q2 revenue rose 22% to $972.2 million, driven by strong sales in collectibles, hardware, and accessories. Profit surged to $168.6 million (31 cents...

Read more

GitLab Boosts Profit Outlook and Beats Q2 Estimates; CFO Departs for Snowflake

by Team Lumida
1 month ago
Gitlab application screengrab

Key Takeaways Powered by lumidawealth.com GitLab raised its full-year adjusted profit forecast after delivering a strong second quarter that surpassed Wall Street expectations. The company beat Q2 estimates on...

Read more

Figma Revenue Soars 41%, But Profit Miss Sinks Stock in First Post-IPO Report

by Team Lumida
1 month ago
a black cell phone

Key Takeaways Powered by lumidawealth.com Figma reported a strong 41% jump in Q2 revenue to $249.6 million, driven by robust growth in large enterprise customers. Despite the impressive top-line...

Read more

Salesforce Beats Earnings But Stock Slips on Weak Outlook and AI Monetization Fears

by Team Lumida
1 month ago
Salesforce Q2 FY25 Earnings Highlights: Strong Growth Led by Integrating AI Solutions

Key Takeaways Powered by lumidawealth.com Salesforce beat Wall Street expectations for Q2 revenue and profit, driven by 11% growth in its core subscription business. Despite the beat, the stock...

Read more

Alibaba’s AI Boom Sparks $50B Rally, Outshining E-Commerce Competition

by Team Lumida
1 month ago
Why Alibaba’s $2.8 Billion AI Investment Could Shake Up the Market

Key Takeaways Powered by lumidawealth.com Stock surge: Alibaba shares jumped 19%+ in Hong Kong, adding over $50B in market cap — its biggest intraday rally since 2022. AI momentum:...

Read more

Dell Raises Full‑Year Outlook, Third‑Quarter View Mixed

by Team Lumida
1 month ago
silver laptop on brown wooden table

Key Takeaways Powered by lumidawealth.com Dell lifted full‑year revenue guidance to $105B–$109B (previously $101B–$105B) and nudged FY EPS midpoint to $9.55 (+$0.10). July-quarter revenue hit $29.78B (+19% YoY) and...

Read more
Next Post
Progyny Q2 2024 Earnings Highlights: Challenges in Utilization Patterns Impact Outlook

Progyny Q2 2024 Earnings Highlights: Challenges in Utilization Patterns Impact Outlook

red and white 8 logo

Reddit Earnings Highlights: Strong Q2 Performance with 54% Revenue Growth

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

Bitcoin Nears $86K as XRP Surges on SEC Resolution and U.S. Futures Launch

March 20, 2025
Bitcoin Mining Stocks Outperform BTC in Early 2025, Network Strength Grows

Bitcoin Defies Market Turbulence, Hits $98,700 While Altcoins Struggle to Recover

February 6, 2025
U.S. Proposes Lifting Oil and Gas Development Restrictions in Alaska Reserve

U.S. Proposes Lifting Oil and Gas Development Restrictions in Alaska Reserve

June 3, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018